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Aims Hyponatraemia has been associated with reduced survival in patients with heart failure and reduced ejection fraction
(HF-REF). The relationship between serum sodium and outcome is unclear in heart failure with preserved (≥50%)
ejection fraction (HF-PEF). Therefore, we used a large individual patient data meta-analysis to study the risk of death
associated with hyponatraemia in HF-REF and in HF-PEF.
Methods
and results
This analysis included 14 766 patients from 22 studies that recruited patients without ejection fraction inclusion cri-
terion at baseline and reported death from any cause. Cox proportional analysis was undertaken for hyponatraemia
(sodium ,135 mmol/L), adjusted for variables of clinical relevance, and stratified by study. The endpoint was death
from any cause at 3 years. Patients with hyponatraemia (n ¼ 1618) and patients with normal serum sodium had
similar characteristics as regards to age, gender, and ischaemic aetiology. However, patients with hyponatraemia
had higher New York Heart Association class and lower blood pressure. At follow-up, there were 335 deaths
among 1618 patients with hyponatraemia (21%) and 2128 deaths among 13 148 patients with normal serum
sodium (16%). The risk of death appeared to increase linearly with serum sodium levels ,140 mmol/L. Hyponatrae-
mia was identified in 1199 HF-REF patients (11%) and 419 HF-PEF patients (11%). Hyponatraemia was independently
predictive of death in both HF-REF [adjusted hazard ratio (HR) 1.69, 95% confidence interval (CI) 1.50–1.91] and HF-
PEF (adjusted HR 1.40, 95% CI 1.10–1.79, P for interaction 0.20).
Conclusion Hyponatraemia is a powerful determinant of mortality in patients with HF regardless of ejection fraction. Further
work is needed to determine if correction of hyponatraemia translates into clinical benefit.
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Introduction
Hyponatraemia (usually defined as a serum sodium concentration
,135 mmol/L)1 is observed in  20% of patients admitted to hos-
pital for heart failure (HF).2–4 Studies conducted in various patient
populations of chronic and acutely decompensated HF have shown
an association between low serum sodium concentration and poor
prognosis.2–7 Most of these studies were focused on short-term
outcomes.2–4 Risk models developed in different HF cohorts of
outpatients8,9 and hospitalized patients10212 have suggested that
hyponatraemia is one of the most powerful predictors of mortality
in HF. Few studies that investigated the relationship between
serum sodium concentration and outcome have included patients
with heart failure and preserved ejection fraction (HF-PEF).2,9,12–14
It is now clear that HF-PEF accounts for a substantial proportion of
cases of HF15,16 and has distinct features compared with heart
failure with reduced ejection fraction (HF-REF).16 The prognostic
role of hyponatraemia has not been well investigated in HF-PEF.
Despite an increasing awareness of the prognostic role of hypona-
traemia in HF, treatment strategies remain elusive and, in recent
clinical trials, vasopressin receptor antagonists did not reduce
mortality.17,18
To overcome the limitations of the previous studies, we com-
bined in the present meta-analysis individual patient data from a
large number of studies [observational studies and randomized
clinical trials (RCTs)] with long follow-up and a large number of
clinical events. Our primary hypothesis was that hyponatraemia
is independently predictive of outcome in both HF-REF and
HF-PEF.
Methods
The design of the Meta-Analysis Global Group in Chronic heart failure
(MAGGIC) meta-analysis was described previously.16 We undertook a
comprehensive literature-based meta-analysis of observational studies
and RCTs published to the end of 2008. In brief, we searched online
databases including Embase, Medline, Medline In-progress, and
PubMed using the key words: prognosis, outcome, heart failure, left
ventricle, and preserved. We also searched reference lists of articles
obtained during the search and conference abstracts, and made per-
sonal contact with the investigators and authors. Abstracts, unpub-
lished studies, and articles published in languages other than English
were not excluded. Eligible studies were those that included patients
with HF without left ventricular ejection fraction (LVEF) entry criterion
and reported death from any cause. We identified 56 potentially suit-
able studies, the principal investigators of which were invited to partici-
pate in the meta-analysis. Investigators (see Appendix) from 30 studies
(two pharmacotherapy RCTs, four management intervention RCTs,
and 24 observational studies) provided individual patient data on a pre-
defined set of variables including demographics, medical history,
medical treatment, symptom status, clinical variables, laboratory vari-
ables, and outcome (all-cause mortality and duration of follow-up).
Data from the individual studies were re-coded at the Coordinating
Centre at the University of Auckland into a uniform format,
checked, and finally incorporated into one database. The data set
included patients who were seen for a baseline assessment either at
an outpatient visit or at the time of a hospital admission. However,
for those studies that recruited patients during an admission, we
have excluded those patients who died during the index admission.
The present analysis included 22 studies that provided serum sodium
concentration (14 766 patients). Preserved LVEF was pre-specified
as LVEF ≥ 50%.16 Serum sodium was available from the baseline as-
sessment in each of these studies, either at an outpatient visit or at dis-
charge from hospital. Hyponatraemia was defined as a serum sodium
concentration ,135 mmol/L.1
Individual studies were approved by Ethics Committees. The
meta-analysis complies with the Declaration of Helsinki and was
approved by The University of Auckland Human Subjects Ethics Com-
mittee. The corresponding author had final responsibility for the deci-
sion to submit the manuscript. All authors have read and agreed to the
manuscript as written.
Statistical analysis
The baseline continuous variables were compared by the use of the
Student’s t-test. The x2 test of proportions was used for categorical
variables. For all analyses, the outcome was the rate of death from
any cause at 3 years from hospital discharge or after the baseline
study visit. Survival analyses used Cox proportional hazard models
with serum sodium as a continuous and categorical variable
(,135 mmol/L and ≥ 135mmol/L). Cox models were stratified by
study and adjusted for age, gender, ejection fraction group, hyperten-
sion, diabetes, atrial fibrillation, and ischaemic aetiology. These vari-
ables chosen for the model were selected for clinical relevance and
each was available in . 90% of the patients in the data set. Estimated
glomerular filtration rate (eGFR) was available in fewer patients.
However, due to its importance in relation to the outcome, the multi-
variable models were re-run after incorporation of this variable into
the above model. The correlation between the scaled Schoenfeld resi-
duals and the length of follow-up showed that there was no violation
of the proportional hazards assumption for all analyses. Mortality
curves were derived from adjusted models.
The relationship between serum sodium concentration and the risk
of death from any cause at 3 years was also explored using spline fits.
For the purpose of deriving informative risk estimates, sodium levels ≤
130 mmol/L or ≥ 146 mmol/L were pooled (due to relatively small
subject numbers outside these values). Cox proportional hazards
models were constructed for the risk of death from any cause with
a sodium concentration of 135 mmol/L as referent. Models were
adjusted for age, gender, hypertension, ischaemic aetiology, atrial fibril-
lation, and diabetes, and stratified by study. The Transreg procedure of
SAS (v9.2) was used to fit spline piecewise polynomials using the
b-spline algorithm. Models were empirically chosen from inspection
of the plots firstly with knots at 137, 140, and 142 mmol/L (quartiles
of the sodium concentration distribution), secondly with a knot at
140 mmol/L, and, finally, with a knot at 135 mmol/L. Confidence inter-
vals (CIs) and prediction intervals were inspected for the plots and the
residuals considered. Parsimony and goodness of fit formed the basis
of model choice, and models were checked for convergence. Analyses
were performed using R version 2.9.0 and SAS version 9.2.
Results
Baseline characteristics
Data on serum sodium concentration were available for 14 766
patients from 22 studies. Patients included in the MAGGIC
meta-analysis had a wide distribution of serum sodium levels
(Figure 1). Median LVEF was 36% [interquartile range (IQR) 26–
48]. Eleven per cent of patients had serum sodium ,135 mmol/L.
The baseline characteristics of patients according to the presence
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or absence of hyponatraemia (defined as serum sodium concentra-
tion ,135 mmol/L) are described in Table 1. Patients with hypona-
traemia (n ¼ 1618) were older, more frequently had diabetes
mellitus and atrial fibrillation, and had worse clinical status
[greater New York Heart Association (NYHA) class, lower systolic
and diastolic blood pressure, and higher heart rate] than patients
without hyponatraemia (n ¼ 13 148) (Table 1). Mean LVEF was
similar in both groups. As regards to medical therapy, patients
with hyponatraemia were more often treated with diuretics,
whereas angiotensin-convering enzyme inhibitors/angiotensin re-
ceptor blockers and beta-blockers were prescribed more fre-
quently in patients with normal sodium levels (Table 1).
Information on prior revascularization was found in the overall
cohort in 10 964 patients (74%). Of these, 269 (21%) patients
with hyponatraemia had been previously revascularized and 2057
(21%) patients without hyponatraemia had been revascularized
Table 2 describes the baseline characteristics of patients with
low serum sodium compared with patients without hyponatrae-
mia, separately for the HF-PEF and HF-REF groups. HF-PEF
patients with hyponatraemia were older, had a more severe clinical
profile, and less angiotensin-convering enzyme inhibitor/angioten-
sin receptor blocker and beta-blocker therapy compared with
HF-PEF patients with normal sodium levels (Table 2). HF-REF
patients with low serum sodium concentration more often had dia-
betes and previous atrial fibrillation, lower LVEF, more severe
clinical forms of HF, and lower prescribed rates of evidence-based
HF drugs compared with HF-REF patients without hyponatraemia
(Table 2). The proportion of patients with hyponatraemia in the
two groups (HF-PEF and HF-REF) was identical: 11%.
Outcome
At follow-up, there were 335 deaths among 1618 patients (21%)
with hyponatraemia and 2128 deaths among 13 148 patients
(16%) without hyponatraemia. Median follow-up was 365 days
(IQR 91–1096) in the overall cohort, 198 days (IQR 86–1096)
in the HF-PEF group, and 365 days (IQR 94–1096) in the
HF-REF group.
When serum sodium concentration was analysed as a continu-
ous variable in the overall cohort, we found a linear increase in
the risk of all-cause mortality at 3 years at concentrations
,140 mmol/L, and a plateau at concentrations ≥ 140 mmol/L
(Figure 2).
In a Cox proportional hazard model adjusted for age and gender
(Table 3), patients with hyponatraemia were at higher risk of death
than patients with normal serum sodium [adjusted hazard ratio
(HR) 1.64, 95% CI 1.48–1.81], and this relationship was observed
for patients with HF-REF (adjusted HR 1.72, 95% CI 1.53–1.93),
and for patients with HF-PEF (adjusted HR 1.36, 95% CI 1.08–
1.72). There was no interaction between LVEF and outcome pre-
diction of hyponatraemia (P for interaction 0.20). After adjustment
Figure 1 Distribution of serum sodium concentration in patients with heart failure and reduced ejection fraction (HF-REF) and in patients
with heart failure and preserved ejection fraction (HF-PEF).
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for age, gender, ejection fraction group, atrial fibrillation, hyperten-
sion, ischaemic aetiology, and diabetes, and stratification by study
(Table 3), hyponatraemia remained a strong independent predictor
of mortality (adjusted HR 1.64, 95% CI 1.47–1.82 for the
whole group; adjusted HR 1.69, 95% CI 1.50–1.91 for HF-REF;
and adjusted HR 1.40, 95% CI 1.10–1.79 for HF-PEF). Mortality
for patients with HF-REF and for patients with HF-PEF according
to the presence or absence of hyponatraemia is displayed
in Figure 3.
Further adjustment for eGFR (11 954 patients with available
eGFR: 8966 with HF-REF and 2988 with HF-PEF) did not influence
the relationship between low serum sodium and mortality
(Table 3). Hyponatraemia remained independently predictive of
death from any cause in the overall cohort (adjusted HR 1.60,
95% CI 1.43–1.78), in patients with HF-REF (adjusted HR 1.64,
95% CI 1.45–1.86), and in patients with HF-PEF (adjusted HR
1.35, 95% CI 1.06–1.72).
Analysis of the risk of death from any cause by LVEF category
(Figure 4) showed increased risk of death associated with hypona-
traemia for moderately reduced LVEF as well as for severely
reduced LVEF.
Discussion
This study resulting from a large individual patient data
meta-analysis demonstrates that serum sodium concentration has
a strong influence on long-term outcome in a wide spectrum of
HF patients with reduced and with preserved LVEF. Patients with
hyponatraemia generally have more severe clinical forms of HF
and are less often treated with angiotensin-converting enzyme inhi-
bitors/angiotensin receptor blockers and beta-blockers. The risk of
all-cause death associated with hyponatraemia (defined as a serum
sodium concentration ,135 mmol/L) is substantial. Moreover, the
excess long-term mortality associated with hyponatraemia is
observed even after adjusting for other major prognostic variables
and is independent of LVEF. Finally, the shape of the relationship
between serum sodium concentration and risk of death suggests
that mortality may increase within the ‘standard’ reference limits
of 135–140 mmol/L compared with levels ≥ 140 mmol/L.
Hyponatraemia is observed in 18–30% of patients admitted to
hospital for HF.2–4,19,20 The prevalence seems to be lower in out-
patients with chronic HF.21 The current data from the MAGGIC
meta-analysis show lower prevalence of hyponatraemia, as com-
pared with previous studies conducted in acute HF. This lower
prevalence of hyponatraemia in our analysis might be due to the
fact that all patients in the MAGGIC cohort were out of hospital
at the time of the baseline data (for the studies that recruited
patients during an admission we have excluded patients who
died during the index admission). According to our results, the
prevalence of hyponatraemia is identical in patients with HF-REF
and in patients with HF-PEF. In both groups (HF-REF and
HF-PEF), hyponatraemia is associated with more severe clinical fea-
tures and less intensive medical therapy. Patients with HF-PEF and
hyponatraemia are older, whereas patients with HF-REF and low
serum sodium are more often diabetics with previous atrial
fibrillation.
In HF, hyponatraemia results from a non-osmotically mediated
increase in arginine vasopressin (AVP) levels in response to arterial
underfilling.22 Stimulation of V1a receptors of the vascular bed
results in increased vascular resistance, while stimulation of the
V2 receptors in the collecting ducts of the nephron leads to
increased water reabsorbtion and dilutional hyponatraemia.23
While in normal physiological states, changes in plasma osmolarity
precede changes in volume in controlling AVP release, this mech-
anism does not hold in HF.24 Non-osmotic release of AVP by
HF-mediated activation of the sympathetic nervous system and
the renin–angiotensin–aldosterone system leads to persistent
renal water reabsorbtion despite a low plasma osmolarity. It is
still unclear whether low serum sodium is merely a marker of a
more advanced underlying disease or if there is a direct association
between the sodium abnormality and reduced survival.
Hyponatraemia has been demonstrated to be an important pre-
dictor of outcome in outpatients with HF8,9,21 and in patients ad-
mitted to hospital for acute HF.2–4,6,10–14 Secondary analyses of
RCTs have linked hyponatraemia to greater in-hospital mortality
and a higher short-term death/rehospitalization rate.3,4,25 In the
Organized Program to Initiate Lifesaving Treatment in Hospitalized
Patients with Heart Failure (OPTIMIZE-HF) registry,2 patients with
low serum sodium concentration hospitalized for acute HF had
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline characteristics of patients according
to the presence or absence of hyponatraemia
Hyponatraemia P-value
No Yes
n (22 studies) 13 148 1618
Age, years (SD) 68 (12) 69 (13) 0.0073
Women, % 35 37 0.078
Medical history
Hypertension, % 45 45 0.93
Myocardial infarction, % 40 37 0.0056
Atrial fibrillation, % 21 25 0.0004
Diabetes mellitus, % 23 30 ,0.0001
Ischaemic aetiology, % 56 55 0.22
Medication
ACE inhibitor or ARB, % 83 77 ,0.0001
Beta-blocker, % 37 31 ,0.0001
Loop diuretic, % 81 84 0.0002
Spironolactone, % 20 33 ,0.0001
Digoxin, % 39 40 0.25
Clinical status
NYHA class
(I/II/III/IV), %
16/45/30/9 16/34/34/16 ,0.0001
Heart rate, b.p.m. (SD) 80 (20) 84 (21) ,0.0001
SBP, mmHg (SD) 134 (26) 127 (27) ,0.0001
DBP, mmHg (SD) 78 (15) 75 (14) ,0.0001
LVEF, %, median (IQR) 36 (27–49) 35 (25–49) 0.042
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; DBP,
diastolic blood pressure; IQR, interquartile range; LVEF, left ventricular ejection
fraction; NYHA, New York Heart Association; SBP, systolic blood pressure; SD,
standard deviation.
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higher in-hospital and early post-discharge mortality when com-
pared with patients with higher serum sodium levels. The associ-
ation between serum sodium concentration and in-hospital
mortality was independent of left ventricular systolic function.2
The Enhanced Feedback for Effective Cardiac Treatment
(EFFECT) study12 had longer follow-up and reported a strong as-
sociation between low sodium levels and 1-year mortality. Serum
sodium levels ,138 mmol/L were predictive of 3-year mortality in
the Seattle Heart Failure Model, but this study did not include
patients with HF-PEF.11 The present analysis of the MAGGIC
data set confirms previous findings and demonstrates that in a
wide range of patients with reduced and with preserved LVEF,
low serum sodium is strongly associated with all-cause mortality
over a 3-year follow-up. The powerful prognostic impact of hypo-
natraemia was still observed after adjustment for other variables of
clinical relevance in HF such as age, gender, diabetes, ischaemic
heart disease, and renal function.
Serum sodium is a modifiable parameter, and changes in serum
sodium concentration seem to influence outcome in patients with
HF.4,26,27 A recent study suggests that patients with decompen-
sated HF who exhibit an increase in serum sodium after hospital
discharge have improved survival compared with patients in
whom serum sodium remains unchanged or decreases.27 It is,
however, still unclear what represents a clinically meaningful
change (increase or decrease) in serum sodium concentration in
HF patients and what is the most appropriate cut-off level of
serum sodium that should be used to define hyponatraemia.2,28
In the OPTIMIZE-HF registry, a ‘U’-shaped relationship was
found between serum sodium concentration and in-hospital mor-
tality, with mortality already starting to increase for sodium
levels between 135 and 138 mmol/L compared with levels
.138 mmol/L.2 A post-hoc analysis from the International Collab-
orative of NT-proBNP (ICON) showed a similar shape for the
association between serum sodium concentration and 1-year mor-
tality in acute HF patients.13 In contrast to these findings, we
observed a linear increase in the risk of 3-year all-cause mortality
at values ,140 mmol/L, and a plateau at sodium levels ≥
140 mmol/L. This suggests that in patients with HF, mortality
may increase within the standard reference limits of serum
sodium (135–140 mmol/L) compared with ≥140 mmol/L.
However, we cannot establish an optimal prognostic threshold
because prediction intervals were relatively wide. Further thera-
peutic studies need to take into consideration these issues and
target exclusively patients with hyponatraemia.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Baseline characteristics of patients with HF-PEF and patients with HF-REF according to the presence or absence
of hyponatraemia
HF-PEF (n 5 3737) HF-REF (n5 11 029)
Hyponatraemia P-value Hyponatraemia P-value
No Yes No Yes
N (22 studies) 3318 (89%) 419 (11%) 9830 (89%) 1199 (11%)
Age, years (SD) 70 (12) 73 (12) ,0.0001 67 (12) 67 (13) 0.47
Women, % 53 57 0.11 29 30 0.35
Medical history
Hypertension, % 60 61 0.58 42 40 0.75
Myocardial infarction, % 25 22 0.097 45 42 0.029
Atrial fibrillation, % 24 25 0.62 20 25 ,0.0001
Diabetes mellitus, % 25 29 0.092 22 30 ,0.0001
Ischaemic aetiology, % 49 44 0.053 59 58 0.8
Medication
ACE inhibitor or ARB, % 68 60 ,0.0001 88 82 0.0002
Beta-blocker, % 37 30 0.0072 37 32 0.0006
Loop diuretic, % 79 82 0.095 81 85 0.0007
Spironolactone, % 15 24 ,0.0001 22 37 ,0.0001
Digoxin, % 28 26 0.45 43 45 0.067
Clinical status
NYHA class (I/II/III/IV), % 25/45/23/7 25/35/23/17 0.0028 13/46/32/9 13/34/37/16 ,0.0001
Heart rate, b.p.m. (SD) 79 (21) 84 (20) 0.001 80 (20) 84 (21) ,0.0001
SBP, mmHg (SD) 143 (28) 140 (29) 0.12 130 (25) 122 (25) ,0.0001
DBP, mmHg (SD) 80 (16) 77 (15) 0.0063 78 (14) 74 (13) ,0.0001
LVEF, %, median (IQR) 59 (54–66) 59 (54–65) 0.53 32 (24–39) 30 (23–38) 0.0006
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; DBP, diastolic blood pressure; HF-PEF, heart failure with preserved ejection fraction; HF-REF, heart
failure with reduced ejection fraction; IQR, interquartile range; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SBP, systolic blood pressure; SD,
standard deviation.
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Given the pathogenic role of AVP activation in HF, the thera-
peutic targeting of AVP action seems a logical approach. Several
AVP antagonists are available and have been tested in clinical
trials. Tolvaptan is a V2 receptor antagonist approved for the treat-
ment of clinically significant hypervolaemic and euvolaemic hypo-
natraemia (serum sodium ,125 mmol/L) in patients with
cirrhosis, HF, or syndrome of inappropriate antidiuretic
hormone. The SALT trials showed that tolvaptan increases
serum sodium and improves hyponatraemia-related symptoms
and quality of life in cases of hypervolaemic or euvolaemic hypona-
traemia.29 Although effective in reducing body weight, increasing
urine output, and reducing congestive symptoms, tolvaptan did
not reduce all-cause mortality, cardiovascular mortality, and HF
hospitalizations in the large Efficacy of Vasopressin Antagonism
in Heart Failure Outcome Study With Tolvaptan (EVEREST)
trial.17 Interestingly, patients included in EVEREST had extremely
high angiotensin-converting enzyme inhibitor and beta-blocker
prescription rates and only 8% had hyponatraemia (serum
Figure 2 Association between serum sodium concentration
and the risk of death from any cause at 3 years. Hazard ratio
(solid line) and 95% confidence intervals are estimated in a
Cox proportional hazards model using spline piecewise polyno-
mials with one knot at 135 mmol/L. The model is adjusted for
age, gender, ejection fraction group, hypertension, ischaemic aeti-
ology, diabetes mellitus, and atrial fibrillation, and stratified by
study.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Relative risk of all-cause death associated with
hyponatraemia (serum sodium concentration
<135 mmol/L)
n All-cause death,
HR (95% CI)
Overall
Model 1 14 766 1.64 (1.48–1.81)
Model 2a 14 766 1.64 (1.47–1.82)
Model 3a 11 954 1.60 (1.43–1.78)
Heart failure with reduced
ejection fraction
Model 1 11 029 1.72 (1.53–1.93)
Model 2 11 029 1.69 (1.50–1.91)
Model 3 8803 1.64 (1.45–1.86)
Heart failure with preserved
ejection fraction
Model 1 3737 1.36 (1.08–1.72)
Model 2 3737 1.40 (1.10–1.79)
Model 3 2988 1.35 (1.06–1.72)
Model 1: adjusted for age and gender.
Model 2: adjusted for age, gender, ischaemic aetiology, hypertension, diabetes
mellitus, atrial fibrillation, and stratified by study.
Model 3: adjusted for age, gender, ischaemic aetiology, hypertension, diabetes
mellitus, atrial fibrillation, estimated glomerular filtration rate, and stratified by
study.
CI, confidence interval; HR, hazard ratio.
aModels 2 and 3 in the overall cohort were also adjusted for left ventricular
ejection fraction (,50% and ≥50%).
Figure 3 Mortality for patients with HF-REF (heart failure with
reduced ejection fraction) and for patients with HF-PEF (heart
failure with preserved ejection fraction) according to the pres-
ence or absence of hyponatraemia. Adjusted for age, gender, aeti-
ology, hypertension, diabetes, and atrial fibrillation.
Figure 4 Adjusted hazard ratios comparing death from any
cause associated with hyponatraemia by groups of left ventricular
ejection fraction.
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sodium ,134 mmol/L). Our analysis suggests that the cut-off for
the serum sodium level is crucial when looking at mortality in
patients with HF-REF and patients with HF-PEF and in designing
future trials of AVP antagonists in HF.
Limitations
The current study has some limitations. While the MAGGIC
meta-analysis has combined the data from a large number of
studies and individual patients, our analysis is limited by the under-
lying limitations of the original individual studies. However, by in-
corporating data from both randomized trials and observational
studies, resulting in a wide range of patients, with long follow-up
and a large number of clinical events, the results are likely to be
an accurate reflection of patients with HF seen in routine clinical
practice. Data on clinical, echocardiographic, and laboratory vari-
ables were not universally available in all studies. The MAGGIC
meta-analysis has included a large number of studies, and to
derive a common data set we were able to collect key covariates.
This provides great statistical power for determining the role of
major variables in relation to outcome. However, the limitation
of such meta-analyses is that data on other variables of potential
relevance are not available in sufficient numbers to be included
in the multivariable models. This is an inherent limitation but
does not preclude using the available data to address important
clinical hypotheses. Cause-specific mortality was not available in
all studies, and therefore we took into consideration only all-cause
mortality. Finally, data were incorporated only from studies that
enrolled patients without an LVEF inclusion criterion at baseline.
Therefore, studies such as I-PRESERVE and PEP-CHF and the nu-
merous individual studies of patients with HF-REF were not
included in this meta-analysis.
Conclusion
The analysis of this large data set combining individual patients
from multiple studies shows that a low serum sodium concentra-
tion is a strong determinant of long-term mortality in a wide spec-
trum of patients with HF, irrespective of LVEF. The excess risk
associated with low serum sodium concentration becomes
obvious below 140 mmol/L. Whether targeting hyponatraemia
based on this cut-off level translates into clinical benefit remains
to be established by future research.
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